Trial Profile

A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cerepetide (Primary) ; Cisplatin; Docetaxel; Durvalumab; Gemcitabine; Paclitaxel
Indications Cholangiocarcinoma; Gallbladder cancer; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oesophageal cancer; Oropharyngeal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Acronyms BOLSTER
Sponsors Lisata Therapeutics

06 Jun 2025 Planned End Date changed from 1 Mar 2026 to 1 Mar 2030.
06 Jun 2025 Planned primary completion date changed from 1 Mar 2026 to 18 Apr 2026.
21 May 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com